Brazil's Anvisa bans advertising of Hypera's slimming pen Semavy

Brazil's health regulator Anvisa prohibited advertising of Hypera Group's weight-loss pen Semavy, citing that only over-the-counter drugs may be marketed. This regulatory action could impact Hypera's sales and market positioning in the growing weight-loss segment, though the company may appeal or adjust its marketing strategy.